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Abstract 
Hematopoietic Stem Cell Transplantation (HSCT) is a curative option for specific non-malignant 
disorders in childhood, including hemoglobinopathies and primary immune deficiencies. Despite 
promising results in the recent years, many issues regarding timing of HSCT, donor selection, 
conditioning regimen and post-transplant care are currently open.  
Here, a cohort of 11 patients with Sickle Cell Disease transplanted after a Treosulfan-based 
conditioning regimen is described showing that this approach is suitable also when alternative 
donors are employed.  
Optimal modalities for HSCT in patients with Hemophagocytic Lymphohistiocytosis (HLH) are 
investigated through the analysis of outcomes of a 109 transplanted children. We demonstrate that 
active HLH should not preclude transplantation and that haploidentical HSCT is associated with 
dismal outcomes.  
Finally, data regarding supportive measure and psychological consequences of HSCT in children 
are presented. 
  
 
Riassunto 
Il trapianto di cellule staminali ematopoietiche (TCSE) è un trattamento curativo per specifiche 
patologie non oncologiche in età pediatrica, tra cui le immunodeficienze primitive e le 
emoglobinopatie. Negli ultimi anni, sono stati ottenuti risultati promettenti, ma non è ancora 
chiaramente definito in quale fase di malattia debba essere effettuato il TCSE, come selezionare il 
donatore, quale regime di condizionamento e quale terapia di supporto sia più efficace. In questo 
lavoro, è stata descritta una coorte di 11 pazienti con Drepanocitosi trapiantati impiegando un 
regime di condizionamento basato sul Treosulfano, dimostrando ottimi risultati anche con l’impiego 
di donatori alternativi. Sono state analizzate le modalità ottimali del TCSE per pazienti con 
Linfoistiocitosi Emofagocitica valutando una coorte di 109 pazienti trapiantati in Italia. È stato 
dimostrato che la malattia attiva al momento del trapianto non preclude il TCSE mentre il trapianto 
aploidentico è un fattore prognostico sfavorevole. Infine, vengono presentati dati riguardanti le 
terapie di supporto e le conseguenze psicologiche a lungo termine del TCSE in età pediatrica.
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Introduction 
Hematopoietic stem cell transplantation (HSCT) is a curative treatment for malignant and non-
malignant disorders but is complex and associated with significant morbidity and mortality.
1
 
Critical elements include timing of HSCT, donor selection, conditioning regimen and strategies 
aimed at the prevention of Graft versus Host Disease (GvHD), organ damage and infections. These 
topics have been addressed by large studies involving patients with malignant disorders (e.g. acute 
leukemia), but few data are available for patients with non-malignant disorders such as immune 
deficiencies or hemoglobinopathies.
2
 This is due to the relative rarity of these disorders and their 
heterogeneity which requires specific data for each individual disorder. 
The aim of this thesis is to provide further data to optimize the modalities of HSCT for patients with 
non-malignant disorders, with a particular focus on Sickle Cell Disease (SCD) and Hemophagocytic 
Lymphohistiocytosis (HLH). 
Chapter 1 provides an overview of the rational for HSCT for children with non-malignant 
disorders. The indications, principles of conditioning regimen and main complications are 
discussed. The second part of the chapter describes the selection of donor with a focus on strategies 
employed to manage the risk of GvHD, graft rejection and delayed immune reconstitution after a 
haploidentical HSCT. 
Chapter 2 describes the use of a recently introduced Treosulfan based conditioning regimen in a 
cohort of 11 patient with SCD transplanted at the Pediatric Hematology-Oncology Clinic, 
Department of Women's and Children's Health, Padua University Hospital. The second part of the 
chapter focuses on a single patient for whom both cerebral vasculopathy related to SCD and 
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autoimmune hepatitis were cured with HSCT, suggesting that occurrence of an autoimmune 
disorder in a patient with SCD may represent an indication for HSCT. 
Chapter 3 describes the outcomes of children with HLH receiving allogeneic Hematopoietic Stem 
Cell Transplantation in Italy between 2000 and 2014. The analysis of this cohort shows that active 
disease should not preclude transplantation, which should be performed preferably using either 
bone marrow or cord blood cells. Since HLA-haploidentical HSCT in patients with HLH is 
currently associated with unsatisfactory outcomes, innovative approaches are warranted. 
Chapter 4 briefly describes other aspects of supportive therapy, quality of life and psychological 
consequences of HSCT investigated as part of the research contribution of this thesis. 
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Chapter 1 
1.1  Hematopoietic stem cell transplantation 
for non-malignant disorders 
Hematopoietic stem cell transplantation is a curative option for a wide range of acquired and 
inherited malignant and non-malignant disorders in children and adults.
1
 It consists in the infusion 
of Hematopoietic Stem Cells (HSCs) and progenitor cells aimed at establishing marrow and 
immune function. The phases of HSCT include: 
1. Planning of the procedure and confirmation of the suitability of recipient and donor 
2. Conditioning regimen 
3. Infusion of hematopoietic stem cells 
4. Management of complications 
5. Engraftment and immune reconstitution 
The HSCs might derive either from the patient itself (autologous HSCT) or from a healthy donor 
(allogenic HSCT). In children with non-malignant disorders, autologous HSCT is rarely performed 
and for the scope of this thesis we will focus on allogenic HSCT. 
1.1.1 Indications for HSCT 
Non-malignant disorders associated with a defect of the HSCs or their progeny are very 
heterogeneous and comprise primary immune deficiencies, autoimmune diseases, defects of the 
HSC itself (e.g. inherited bone marrow failure syndrome) and disorders of red blood cells (e.g. 
hemoglobinopathies), platelets or metabolism.
3
 For these conditions, HSCT is a curative option, but 
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it is associated with a risk of transplant-associated morbidity and mortality. Thus, the selection of 
the subset of patients eligible for HSCT is a critical point in order to minimize the adverse effects. 
Eligibility criteria should be determined for every single condition based on the knowledge of the 
natural history of the disease and the expected benefit of the HSCT. Broadly, conditions to be met 
for HSCT in non-malignant disorders include clear and confirmed diagnosis, severe phenotype, 
suitable general condition of the patient and the availability of a donor.
2
 For chronic non-malignant 
disorders for which an alternative treatment is available, also the timing of HSCT is critical. If the 
HSCT procedure is performed too early, patients with a milder phenotype might be included. 
Conversely, if HSCT is performed too late, the disease might progress and impede the HSCT.
4
 The 
treatment preceding HSCT should be aimed at reducing the organ damage associated with the 
underlying disorder and controlling its manifestations in order to reduce the risks associated with 
HSCT. Finally, indications for HSCT in a specific disorder vary over time as new alternative 
treatments become available or advances in the HSCT procedure allow to improve the outcomes.
5,6
 
All these data should be generated and reviewed over time for every single disorder since intrinsic 
differences in the pathophysiology influence largely the modalities and outcomes of HSCT. 
1.1.2 Conditioning regimen 
The conditioning regimen acts both on the recipient HSCs and immune system to allow the 
engraftment of the infused HSCs. The conditioning regimen needs to provide enough 
myelosuppression to eradicate the recipient HSCs and “create space” within the hematopoietic 
niche for donor HSC. The second objective is to eliminate the immune response of the recipient in 
order to prevent the immune-mediated rejection of the graft. These objectives are accomplished by 
the administration of chemotherapeutic and immuno-modulating agents and/or radiation therapy in 
the weeks immediately preceding the infusion of the HSCs. In order to clarify the reasons why 
specific conditioning regimens are currently employed for non-malignant disorders, a historical 
perspective is useful. The first HSCT were performed to rescue patients from long term bone 
marrow failure secondary to the accidental exposure to ionizing radiation.
1
 Given its cytotoxic 
effect on the tumor cells, total body irradiation was employed for HSCT in patients with leukemia. 
Subsequently, agents mimicking the effect of radiation on human cells (e.g. busulfan) were 
developed and employed for HSCT. When first patients with non-malignant disorders were 
transplanted, the conditioning regimens were adapted from the established regimens for leukemia 
patients. In the recent years, development of innovative conditioning regimens were based on the 
understanding of the specificities of each disorder.
7
 
The agents employed in conditioning regimens have a myeloablative and/or immunosuppressive 
effect, but are also associated with significant toxicities on other organs. This issue is especially 
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important for patients with non-malignant disorders due to the significant organ damage caused by 
the underlying disease. To mitigate the regimen related toxicity, reduced intensity conditioning 
regimens (RIC) have been designed and employed.
8
 However, as the toxicity is reduced, also the 
myeloablative and immunosuppressive potential might be affected, possibly leading to a higher risk 
of graft rejection or to coexistence of donor and recipient hematopoiesis. As the ultimate goal of 
HSCT is the cure of the patient more than the establishment of a donor derived hematopoietic 
system, the presence of recipient-derived HSCs alongside with the donor-derived HSCs might be 
tolerated as long as the “healthy” cells allow for the remission of the manifestation of the disorder 
(mixed chimerism).
7,9,10
 
The most frequently employed drugs for conditioning in non-malignant disorders include alkylating 
agents (Busulfan, Treosulfan, Cyclophosphamide, Melphalan and Thiotepa), antimetabolites 
(Fludarabine) and epipodophyllotoxins (Etoposide). Monoclonal antibodies against lymphocytes 
such as antithymoglobulin (ATG) or anti-CD52 antibody (Alemtuzumab) are widely employed to 
prevent graft rejection and GvHD.
11
 Historically, the first established conditioning regimen 
included busulfan, which is associated with significant toxicity and new approaches have been 
implemented. The unpredictable pharmacokinetics of busulfan was managed with a therapeutic 
drug monitoring approach which ensures a targeted dose of busulfan for each patient.
12,13
 More 
recently, treosulfan has been reported as a valid alternative to busulfan, due to its more predictable 
pharmacokinetic profile and the reduced risk of complications.
14,15
 Another approach proposed is 
the use of a less intense conditioning regimen with fludarabine and melphalan which is highly 
immunosuppressive and less myeloablative. However this approach was associated with a 
significant risk of rejection and GvHD, especially in patients with sickle cell disease and 
hemophagocytic lymphohistiocytosis.
16–18
 
1.1.3 Complications after HSCT 
HSCT is associated with a wide range of adverse events and complications that are responsible for 
the transplant related morbidity and mortality. A frequent complication limiting the employment of 
allogenic HSCT is Graft versus Host Disease (GvHD). GvHD arises when the lymphocytes derived 
from the donor mount an immune response against to the tissues of the recipient which are not 
recognized as self.
19
 The most important proteins responsible for the recognition of the foreign 
antigens are human leukocyte antigens (HLA), which are expressed on the surface of nucleated 
cells with a higher frequency on immune cells and on epithelia. GvHD is classically divided in an 
acute form occurring in the first 100 days after HSCT and involving especially the skin, gut and 
liver, and a chronic form, occurring later than 100 days post HSCT and involving almost all organs 
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and tissues. The mainstay of prevention and treatment of GvHD is the use of immunosuppressive 
agents such as calcineurin inhibitors (Cyclosporine A and Tacrolimus) and steroids.
20
 
Other HSCT complications might be due to regimen related toxicity, prolonged aplasia, delayed 
immune reconstitution or failure of infused HSCs. Early post HSCT complications include 
infections and regimen related toxicity involving all major organs. Infections occurring post 
transplant are frequent and diverse, including also agents that cause disease only in the 
immunocompromised host. Frequent etiological agents include bacteria (both Gram-positive and 
Gram-negative), fungi (e.g. Aspergillus spp and Candida spp) and virus (e.g. EBV, CMV, 
Adenovirus).
21
 Regimen related toxicity frequently include risk of bleeding, damage of the mucosae 
(mucositis), liver and renal impairment, and more rare manifestation such as veno-occlusive 
disease, thrombotic microangiopathy, cardiac or neurological toxicity.
2
 Late effects post HSCT are 
defined as occurring more than 3 months after HSCT and provoking health restriction for long term 
survivor. The presence of a late effect might impair the quality of life of the patient, hampering the 
complete cure of the disease. Almost all organs and systems can be affected depending on the type 
of transplant and drug employed. The most often observed late effects include ocular disorders 
(cataracts), thyroid dysfunction, sterility and metabolic disorders.
22
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1.2 Donor choice and Haploidentical Stem 
Cell Transplantation 
Published as: Tumino M., Marzollo A., Gazzola M., Calore E., Mainardi C., Pillon M., Destro R., 
Gabelli M., Strano A., Barioni M., Messina C. Cell Manipulation in Pediatric Haploidentical 
Stem Cell Transplantation: State of the Art. J Pediatr Biochem. 2016;5(4):115-119. 
doi:10.1055/s-0036-1572322. 
 
The selection of the donor for allogenic HSCT is an important step in the preparation of the 
transplant. The most important factor for the donor choice is the compatibility between donor and 
recipient in order to reduce the risk of graft rejection and GvHD. The donor-recipient compatibility 
is genetically determined and requires the matching for a very polymorphic locus which encodes for 
proteins known as human leucocyte antigen (HLA). Also other loci (minor histocompatibility 
antigens) have a role in the risk for rejection and GvHD, but are not usually taken into consideration 
when a donor is selected. The preferred donor for HSCT is a healthy HLA-matched sibling, who 
shares not only the same alleles encoding for HLA but is also more likely to share other minor 
histocompatibility antigens. Unfortunately, less than one-third of patients in need for HSCT has an 
HLA-matched sibling donor. Alternative donors such as matched unrelated matched (MUD) or 
mismatched cord blood units, or three-loci mismatched haploidentical family donors are 
increasingly used as sources of hematopoietic stem cells. The probability of identifying a MUD in 
worldwide donor registries is dependent on the diversity of HLA antigens within a population and 
on the ethnical background of the patient. In addition, a MUD donor search is time-consuming and 
the time from start of a donor search to the actual transplant is around four to six months. A 
significant number of patients will experience disease progression or even die within the time of 
donor search, and the potential life-saving allogeneic HSCT will no longer be a therapeutic option. 
HLA-haploidentical donors share with the patient only one allele containing the HLA loci and are 
available for nearly every individual. The haploidentical donor could be any healthy parent, 
approximately half of all siblings and potentially even more distant relatives with a shared 
haplotype. In pediatric patients the parents are usually employed, but haploidentical relatives such 
as aunts or uncles can also be chosen in the rare cases when no parental donor is available or the 
parent is medically unfit for donation.  
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1.2.1 HLA complex and HLA-haploidentical transplantation 
The HLA locus encodes proteins responsible for cell surface antigen presentation. There are two 
main classes of HLA proteins: class I (A, B and C locus) and class II (DP, DQ and DR locus). HLA 
class I genes are constitutively expressed by most cell types. HLA class I molecules present 
intracellular peptides that are processed in proteasomes and direct CD8+ cytotoxic T-cells towards 
the elimination of infected cells or cells expressing aberrant peptides. HLA class II genes are 
constitutively expressed on hematopoietic cells involved in antigen presentation. Their molecules 
present peptides derived from the fusion of endocytic vesicles with lysosomes and direct CD4+ T 
cells towards extracellular epitopes. HLA molecules are expressed on every cell and can elicit a 
strong immune response. Therefore host HLA molecules not present in the donor are a major 
determinant of the graft-versus-host reaction. Conversely, alloreactivity occurring in the opposite 
direction is responsible of graft rejection.  
The multigene HLA family has at least 12 polymorphic loci with a strong linkage disequilibrium 
among the alleles. DNA-amplification methods for typing class I and II HLA alleles have 
confirmed the extensive polymorphism of the HLA system initially documented in serologic studies 
and have defined alleles that could be identified serologically. In the late 1990s, the Japan Marrow 
Donor Program (JMDP) demonstrated for the first time the effect on acute GvHD of matching not 
only HLA class I antigens (serologically) but also alleles (gene sequencing) and the importance of 
HLA-A and -B allele matching for survival.
23
 Analysis of a large cohort in the United States also 
indicated that HLA allele mismatching is a significant risk factor for severe acute GVHD and 
mortality.
24
 Subsequent extensive analysis of the JMDP, US National Marrow Donor Program 
(NMDP), European registries and the International Histocompatibility Workshop Group (IHWG) 
provided strong evidence that HLA allele compatibility, HLA haplotype, HLA epitope and amino 
acid substitution at peptide-binding pockets of HLA class I molecules are also significantly 
associated with clinical outcomes such as severe GvHD and mortality.
25–38
 
In the setting of haploidentical HSCT, only one of the two HLA-haplotypes is shared: the unshared 
haplotype encodes allogeneic HLA molecules that strongly activate the immune system leading to 
graft rejection or GvHD. 
1.2.2 Graft Manipulation Strategies 
Until 1990s, haploidentical HSCT was performed only in extreme clinical conditions due to high 
incidence of graft rejection or severe GvHD. These events are mediated by T cells that recognize 
major class I or II HLA disparities between donor and recipient. To overcome these issues, 
strategies directed towards the modulation of T cell response have been developed. Two main 
approaches have been proposed and gained approval: ex-vivo T-cell depletion (TCD) with 
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“megadose” CD34+ cells, and T-cell replete unmanipulated grafts with novel immunosuppression 
strategies for GvHD prophylaxis. 
1.2.2.1 T-cell depletion with “megadose” CD34+ grafts 
Since 1976, many techniques were developed to remove T cells from the graft before infusion. 
Soybean agglutinin and erythrocyte-rosetting with sheep erythrocytes was first used at the 
Memorian Sloan Kattering Cancer Center. This method can separate T cells from B cells and 
hematopoietic stem cells. No lethal GvHD was observed in murine models and in the clinical 
setting this procedure resulted in sustained engraftment without GvHD.
39–41
 Unfortunately, anti-
donor T-cells in the host could destroy the infused cell product resulting in graft rejection in nearly 
20% of the cases.
42–47
 
A novel transplantation platform was created in Perugia in order to improve engraftment following 
a T cell depleted haploidentical transplantation.
48
 Recipient T cells were destroyed by the 
intensification of conditioning regimen, adding alkylating agents or Thiotepa, total body irradiation 
(TBI) or booster splenic irradiation, and anti-thymocyte globulin (ATG).
49–53
 Secondly, a very high 
stem cell dose (“megadose”) obtained using a combination of donor bone marrow and GCSF-
mobilized peripheral blood stem cells (PBSCs) resulted in a “veto effect”: the large number of 
CD34+ cells directly inhibited T-cell alloreactivity.
50,54–56
 Early clinical results in patients affected 
by acute leukemia demonstrated that intensive immunosuppressive conditioning with a T-Cell 
depleted “megadose” allograft could reduce the rates of graft failure and GvHD.57,58 The complete 
T cell-depletion in the graft eliminated also the need of post transplant immunosuppression as 
GvHD prophylaxis. 
In the following years other approaches have been proposed. The use of positive selection of CD34 
positive cells from PBSCs showed a low rate of graft failure and acute and chronic GvHD. 
However, there was a significant delay of the immune reconstitution, especially for CD4+ T cells. 
This caused a 40% non-relapse mortality (NRM), with 65-71% of deaths due to infections.
58,59
  
To overcome the high mortality due to infection in patients receiving haploidentical grafts 
containing only highly purified CD34+ cells, more sophisticated graft manipulation strategies were 
envisaged. Based on the capability of monoclonal antibodies to discriminate among different 
population of immune cells, new platforms incorporate the possibility to infuse only selected 
subsets of B and T cells. The aim is to obtain the “perfect graft” which would lead to no GvHD 
while preserving the capabilities of the infused cells to respond to infectious agents, kill malignant 
cells and destroy residual host T cells. 
The first experience was based on eliminating from the graft CD3+ T cells (comprising T helper 
and T cytotoxic cells) and CD19+ B cells. B cell depletion was done in order to reduce both the risk 
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of post-transplant EBV-related lymphoprolipherative disease and the incidence of chronic GvHD. 
Compared to the CD34+ positive selection, this approach allowed to infuse in the host a larger 
number of myeloid cells that could control infection after the transplant. The obtained results were 
promising but overall EFS remained about 50-60%. The main reason is that this platform was 
mainly offered to high risk patients after the second relapse or with refractory malignant 
disease.
60,61
 
Further technological advancement came from the knowledge about how different subpopulation of 
immune cells could modulate the occurrence of GvHD, post-transplant infections and the 
destruction of malignant cells. In particular, TCRαβ positive T cells are implicated in the GvHD 
pathogenesis while TCRγδ positive T cells do not mediate any immune response against the host, 
protect from infections and destroy leukemic cells.
62
 This observation led to the development of a 
transplantation platform in which TCRαβ positive and CD19+ cells are depleted from the graft.63 
The results of this technique are extremely promising showing a disease free survival above 80% in 
patient with non-malignant disease, similar to matched unrelated donor transplantation.
64,65
 
Recently data regarding children with advanced hematological malignancies have confirmed these 
excellent results.
66
 
1.2.2.2 T-cell replete unmanipulated grafts with novel immunosuppression strategies for GvHD 
prophylaxis  
Graft manipulation techniques are costly and require adequate facility and expertise to be 
performed. The observation that proliferating alloreactive T cells are more sensible to high dose 
cyclophosphamide than stem cells, resting T cells or T regulatory cells has prompted the use of this 
drug for the prevention of GvHD and graft rejection.
67
 Luznik and the Baltimore group have 
designed a protocol in which high dose cyclophosphamide (50 mg/kg) is given on day 3 and day 4 
after infusion of unmanipulated haploidentical bone marrow cells. In addition, patients receive a 
two drug GvHD prophylaxis (Mycophenolate and Cyclosporine) and G-CSF. Luznik et al. 
demonstrated that this approach is feasible and efficacious in the preclinical model, in patients with 
hematologic malignancies and in patients with non-malignant disorders.
68–70
 Furthermore, the wide 
availability of cyclophosphamide and the absence of stem cell manipulation renders this protocol 
applicable in many low resource countries.
71
 Usually this type of haploidentical transplant includes 
a reduced intensity conditioning and this could explain why it has been mainly used in adults, even 
above 65 years of age. A recent large prospective trial comparing double umbilical cord blood 
transplant with this type of haploidentical transplant has shown comparable result between the two 
platforms. For haploidentical transplantation, the incidence of grade II-IV acute GvHD was 32% 
and the primary graft failure rate was as low as 4%.
72
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1.2.3 Eligibility and advantages of haploidentical transplantation 
Traditionally, haploidentical HSCT was reserved only for high risk patients with no other curative 
options like relapsed or refractory hematopoietic malignancy or severe congenital 
immunodeficiency (SCID), in which the high mortality makes transplant an “urgent” procedure. 
Since the introduction of innovative techniques in the field of haploidentical transplantation, 
transplant related mortality is comparable with other alternative stem cell sources such as cord 
blood or matched unrelated donor.
66
 
Haploidentical HSCT has some biological and practical aspects that could make it preferable to 
other alternative stem cell sources: 
1. Immediate availability of the donor at the time of transplant: haploidentical donor is 
immediately available for the patients in urgent need (such as high risk leukemia or 
severely compromised SCID patients) 
2. Possibility to collect a large number of donor cells, either for a “megadose” transplant or 
for stem cell manipulation 
3. Anti-infectious and anti-tumor activity mediated by alloreactive NK or T cells, if 
specific manipulation strategies are employed 
4. Prompt donor availability after the HSCT to collect or generate additional cells and 
enhance antitumor effects or improve immune reconstitution.  
1.2.4 Conclusion 
HLA-haploidentical transplantation has historically been associated with poor outcomes, owing to 
high rates of graft failure and graft-versus-host disease (GVHD). In more recent years, several 
transplantation platforms have been developed in order to overcome these barriers, with different 
results. No standard-of-care currently exists and randomized prospective studies are warranted to 
compare these different techniques. The haploidentical donor as a source for stem cells needs also 
to be compared with other alternative cell source like umbilical cord blood or matched unrelated 
donor. These comparisons may yield different results in settings differing in the proportion of 
malignant vs non-malignant disorders, experience of the treating center or resource availability. 
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Chapter 2  
2.1 Treosulfan-Based Conditioning 
Regimen for Sibling and Alternative 
Donor HSCT for Children with Sickle 
Cell Disease. 
Published as: Marzollo A., Calore E., Tumino M., Pillon M., Gazzola MV., Destro R., Colombatti 
R., Marson P., Tison T., Colpo A., Mainardi C., Gabelli M., Boaro MP., Rossin S., Strano A., 
Quaglia N., Menzato F., Basso G., Sainati L., Messina C. Treosulfan-Based Conditioning 
Regimen in Sibling and Alternative Donor Hematopoietic Stem Cell Transplantation for 
Children with Sickle Cell Disease. Mediterr J Hematol Infect Dis. 2017;9(1):e2017014. 
doi:10.4084/MJHID.2017.014. 
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Abstract 
Background and objectives Lack of suitable donors and regimen related toxicity are major barriers 
for hematopoietic stem cell transplantation in patients with sickle cell disease. The aim of the study 
is the assessment of efficacy and toxicity of Treosulfan-based conditioning regimen for SCD also 
when alternative donors such as mismatched unrelated donor and haploidentical donor are 
employed. 
Methods We report our single-center experience: 11 patients with sickle cell disease received HSCT 
with a Treosulfan/Thiotepa/Fludarabine/Anti-thymoglobulin conditioning regimen between 2010 
and 2015. The donor was a matched sibling donor (n= 7), a haploidentical parent (n= 2), a matched 
unrelated donor (n= 1) or a mismatched unrelated donor (n=1). The haploidentical and mismatched 
unrelated donor grafts were manipulated by removing TCRαβ and CD19 positive cells.  
Results All patients survived the procedure and achieved stable engraftment. Stable mixed 
chimerism but no SCD manifestation was observed in 5/11 patients. Grade III-IV regimen related 
toxicity was limited to mucositis and no grade III-IV graft-versus-host disease (GvHD) was 
observed. Organ function evaluation showed no pulmonary, cardiac or renal toxicity; cerebral 
vasculopathy improved in 3/5 evaluable patients. Gonadal failure was observed in 1/4 evaluable 
patients.  
Conclusion Our data suggest that Treosulfan is associated with low toxicity and may be employed 
also for unrelated and haploidentical donor HSCT. 
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2.1.1 Introduction 
Sickle cell disease is the most frequent haemoglobinopathy worldwide. A point mutation in the 
beta-globulin gene alters the hemoglobin structure and results in chronic hemolytic anemia and 
increased blood viscosity. This leads to an heterogeneous phenotypic spectrum: increased morbidity 
and mortality is due to a higher susceptibility to infections, intermittent vaso-occlusive events and 
ischemic tissue injury with progressive organ dysfunction.
73
 Hematopoietic stem cell 
transplantation is the most consolidated curative treatment.
74
 When considering HSCT for SCD 
patients, expected SCD morbidity should be balanced against the risk of transplant related mortality 
and morbidity, keeping in mind that SCD is a non-neoplastic disease with a life expectancy of over 
50 years with contemporary treatment.
75
  
More than 200 patients transplanted with a matched sibling donor (MSD) after a myeloablative 
conditioning regimen based on Busulfan and Cyclophosphamide. The limitations associated with 
this strategy are the significant regimen related toxicity and the risk of graft failure. The transplant 
associated mortality is around 2-8% and graft failure is observed in around 10-15% patients.
76–83
 
Although better outcomes have been recently reported with the use of targeted Busulfan therapy, 
the use of Busulfan-based conditioning regimen is established only in the setting of MSD transplant 
but only few SCD patients in need of a HSCT have a matched sibling available.
84–87
 The use of 
alternative donors such as matched unrelated donor (MUD), mismatched unrelated donor (MMUD), 
unrelated umbilical cord blood (UCB) and haploidentical family members is associated with a 
higher mortality and morbidity, due to pre-existing organ dysfunction, alloimmunisation and risk of 
GvHD.
74,88
 Moreover, suitable matched unrelated donors are difficult to find and experience is 
limited for umbilical cord blood or haploidentical donor HSCT.
89–93
 In order to overcome the limits 
of the Busulfan-based conditioning regimen and allow the use of alternative donors, different 
conditioning strategies have been proposed.
17,94
 Recently, Treosulfan became attractive to substitute 
Busulfan due to its lower toxicity and good immune suppressive and myeloablative potential.
14,95–98
 
This led to the use of Treosulfan in patients with pre-existent morbidity (mainly primary immune 
deficiency or β-thalassemia) or receiving a second transplantation for malignant disorders.95,96,99–105 
For these reasons, since 2010 at our institution Busulfan was substituted with Treosulfan as 
standard conditioning regimen for SCD patients. 
We present our single-Centre experience of HSCT performed for SCD patients employing 
Treosulfan-based conditioning regimen also in haploidentical and MUD HSCT . 
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2.1.2 Methods 
From April 2010 to December 2015, all SCD patients undergoing HSCT received a Treosulfan-
based conditioning regimen and are described in this retrospective cohort study. Eligibility for 
HSCT was determined on the basis of published guidelines and criteria included cerebral 
vasculopathy, recurrent episodes of acute chest syndrome (ACS) or vaso-occlusive crises despite 
hydroxycarbamide treatment.
106
 Donors were chosen on the basis of availability and considered in 
the following order: MSD, MUD, Haploidentical donor and MMUD. The preferred stem cell source 
was bone marrow or umbilical stem cells for MSD, bone marrow for MUD and T-depleted 
peripheral blood stem cell for haploidentical donors and MMUD. The use of a combination of 
umbilical cord blood and bone marrow was employed in MSD HSCT if the cellularity of the 
umbilical cord graft was low.
92
 Before T-cell depleted HSCT or MUD, autologous bone marrow 
stem cells were harvested and cryopreserved in order to be re-infused in case of graft rejection, due 
to the higher risk of this event after T-cell depletion.
107
 Before HSCT, all patients received either 
red cell exchange transfusion or simple transfusion the day before the start of conditioning regimen 
in order to obtain a proportion of HbS < 30% and a Hb level ≥ 100g/L. 
The haploidentical donors underwent PBSC collection after mobilization with subcutaneous 
Filgrastim 10 µg/Kg twice daily from day -5 to day -1 and once on the day of collection. PBSC 
were collected using a COBE® Spectra Apheresis System (BCT Terumo, Lakewood, CO). T-cell 
depletion was performed by removing TCR alpha/beta positive and CD19 positive cells through 
immuno-magnetic selection (CliniMACS; Miltenyi Biotec, Bergisch Gladbach, Germany).  
All patients received Thiotepa (8 mg/kg or 10 mg/kg in 2 doses on day -7), Treosulfan (14 
g/m2/day for 3 days from day -6 to day -4 ) and Fludarabine (40 mg/m2/day for 4 days from day -6 
to day-3).
99
 Fresenius® anti-thymocyte globulin (ATG) at the dose of 20 mg/kg/day were 
administered for 3 days in MSD and MUD transplants and 5 mg/kg/day for 4 days in haploidentical 
transplants. Patient 8 and patient 11 received Rituximab (200 mg/m2) at day -1 to reduce the risk of 
EBV reactivation and GvHD after HSCT.
64
 Graft-vs-Host Disease (GvHD) prophylaxis for T-
replete transplants consisted in Cyclosporine 1 mg/kg/day on days -7 to -2, short term Methotrexate 
(10mg/kg for 4 doses) and Cyclosporine aiming at a pre-dose level of 100-200 µg/L for 6 months. 
No GvHD prophylaxis was given for T-deplete transplants . The supportive measures, diagnosis 
and treatment strategy for acute GvHD employed at our institution were recently described.
108
 
Engraftment was serially tracked after HSCT. Samples were obtained every 2-3 weeks up to day 
+100 and monthly thereafter up to 18 months post transplant in patient with complete donor 
chimerism. Follow up was longer for patients with mixed chimerism. Chimerism analysis was 
performed by PCR testing for informative short tandem repeats. Adverse events were graded 
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according to common terminology criteria for adverse events (CTCAE) v4. Neutrophil and platelet 
recovery were defined as an neutrophil count ≥ 0.5×10^9/L for 3 consecutive days and as a platelet 
count ≥ 50×10^9/L independently of platelet transfusions for 7 consecutive days.  
Organ function was assessed pre-transplant and every year post-transplant by pulmonary function 
testing, echocardiography, growth and puberty evaluation and hormonal dosage 
(estradiol/testosterone, FSH, LH, T4 and TSH levels). Transcranial Doppler Ultrasonography 
(TCD) was performed for all patients prior to the initiation of chronic transfusion and pre-HSCT; 
data were evaluated according to the criteria defined by the STOP trial.
109
 Brain magnetic resonance 
imaging (MRI) and magnetic resonance angiography (MRA) were performed pre-transplant, and 
repeated one year post transplant and every two years thereafter if lesions were detected. Immune 
reconstitution was evaluated by total lymphocyte count, CD4+ cell count and immunoglobulin 
dosage. Data were recorded at day +30, +90, +180 and +365. 
2.1.3 Results 
2.1.3.1 Patients 
Eleven consecutive children affected by SCD (7 females, 4 males) were transplanted in the 
Pediatric Hematology and Oncology Department of Padova University Hospital. The origin of 
patients was African (n = 6), Caucasian (n = 4) or Caribbean (n = 1). Patient and transplant 
characteristics are summarized in Table 1. Seven patients were diagnosed at birth due to family 
history, the remaining at their first disease manifestation, between 7 month and 5 years of age. The 
Hb genotype was HbSS (n = 10) or HbSβ0 (n = 1, P7). Before transplant patients were treated with 
chronic transfusion (n = 7), monthly red cell exchange transfusion (n = 2) and/or hydroxycarbamide 
(n = 5). Patients were eligible for HSCT due to cerebral vasculopathy (n=7), recurrent episodes of 
acute chest syndrome (ACS) or vaso-occlusive crises despite hydroxycarbamide treatment (n = 4). 
Patient 7 suffered also recurrent splenic sequestration.
106
 The median age at transplant was 6.5 years 
(range: 4 – 16.3 years). At the time of transplant, only two patients had significant comorbidities: 
relapsing autoimmune hepatitis (P8) and an association of Chiari I malformation and syringomyelia 
(P11). Donor source was a HbS/A MSD (n = 5), a HbA/A MSD (n = 2), a haploidentical HbS/A 
parent (mother, n = 1 and father, n = 1), HbA/A MUD (n = 1) or HbA/A MMUD (n=1, 8/12 HLA 
loci donor/recipient matching). Stem cell source were bone marrow (n=6, median total nucleated 
cells, TNC = 4,9 x 10^8/kg), combined bone marrow and umbilical cord blood (n=2, median TNC 
for bone marrow = 2,67 x 10^8/kg; median TNC for cord blood = 2,44 x 10^7/kg) or peripheral 
blood stem cells (PBSC) (n=3, two haploidentical grafts and one MUD graft, median CD34+ cells = 
14,3 x 10^6/kg). One apheresis was sufficient to reach the target dose of CD34+cell (10 x 10^6/kg 
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recipient) in both haploidentical donors. Both donors complained only grade I-II myalgia and 
fatigue.  
 
2.1.3.2 Transplant-related outcomes 
All patients achieved neutrophil and platelets engraftment at a median of 20 days (range: 15-34 
days) and 22 days (range: 12-31 days) from HSC infusion, respectively. No patient experienced 
primary graft failure. All patients experienced Grade III anemia, grade IV thrombocytopenia and 
grade IV neutropenia. Grade III-IV non hematological toxicity occurred in 2 patients and consisted 
in grade IV stomatitis in one patient and acute disseminated encephalomyelitis in one patient. All 
toxicity resolved completely. Grade I-II gastrointestinal acute GvHD was diagnosed in 3 patients 
(haploidentical transplant, n = 1; MUD transplant, n = 1, MMUD transplant, n=1). These patients 
were successfully treated with calcineurin inhibitors (n = 3), steroids (n = 1) and extracorporeal 
photochemotherapy (n = 3) as per institutional protocol.
108
 No grade III-IV acute GvHD or chronic 
GvHD were observed. No secondary graft failure was observed.  
In 6/11 patients a full donor chimerism was demonstrated. Stable mixed chimerism was observed in 
5 patients (45%). Donor hematopoiesis ranged from 37% to 90%, but did not affect the HbS 
proportion: HbS was absent after a transplant from HbA/A MUD (n=1) or compatible with HbS 
carrier (median 40.5%, range 40.3-41,4%) in patients transplanted from a HbS/A MSD (n=4). 
The lymphocyte count reached normal values for age at day +180 in all patients except P11. Median 
time to reach a CD3+CD4+ cell count higher than 400/µL was 148 days for T-replete grafts (range 
57-203 days) and 245 days (range 237-253 days) for T-deplete grafts. Immunoglobulin replacement 
was necessary only in one patient (P11) who experienced EBV reactivation and received one dose 
of rituximab. Despite serial monitoring no viral reactivations were documented in any other patient. 
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Table 1 Patient characteristics and outcomes. Abbreviations: ATG = antithymoglobulin; FLU = fludarabine in mg/m2; RITUX = rituximab; TREO = Treosulfan in 
g/m2; TT = Thiotepa in mg/kg. 
 22 
 
2.1.3.3 Organ damage and SCD-related outcomes 
The median follow-up was 2.35 years (range: 0.8-6.5 years). All patients are alive and well. No 
episode compatible with acute chest syndrome, stroke or other sickle cell disease manifestation 
occurred. No patient experienced renal or hepatic dysfunction following transplantation. TCD 
was normal for patients without cerebral vasculopathy. Data for patients with cerebral 
vasculopathy are reported in Table 2. Brain MRI and MRA data are available for 10 patients. 
Three patients had normal pre-transplant brain imaging. Two patient had cerebral vasculopathy 
before transplantation, but no post transplant imaging. Five patients had alteration on the pre 
transplant MRI and evaluable data on follow-up (Table 3). Resolution or improvement of the 
Table 3 Transcranial Doppler Ultrasonography for patients with cerebral vasculopathy. Results were categorized as 
normal, conditional or abnormal according to the STOP trail criteria.
109
 n/a: not available. 
Table 2 Brain imaging before and after HSCT for patients with cerebral vasculopathy. WHM: white matter 
hyperintensity; n/a: not available 
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vascular stenosis was detected in 3/5 patients. The last post-transplant evaluation was performed 
after a median of 1315 days (range: 268-1417).  
Pre-transplant organ function was within normal limits for all patients. Post-transplant lung 
function evaluation was performed in 7 patients (P1-3 and P5-8) and was normal for all of them 
after a median of 1104 days from transplant (range 369-2304 days). Hormonal function was 
evaluated 7 patients (P1-3 and P5-8) after a median of 804 days from transplant (range 205-1518 
days). Height and weight growth and thyroid function was normal for all explored patients. 
Three patients were pre-pubertal at last assessment. Puberty was evaluable in 4 patients (P1, P2, 
P5 and P8: 1 male and 3 females) and they all had normal pubertal development. Follow up 
echocardiography (data available for 7 patients) and eye examination (data available for 5 
patients) were normal. 
2.1.4 Discussion 
We report a retrospective case series of 11 SCD patients who received HSCT after a Treosulfan-
based conditioning regimen. Sustained engraftment was observed in all patients. Stable mixed 
chimerism was detected in a significant proportion of patients (45%), did not change after the 
discontinuation of immunosuppressive treatment and resulted in a cure of SCD for all patients. 
Previous experiences have demonstrated that full donor chimerism is not needed to cure SCD 
due to the survival advantage for donor red cell in peripheral blood: pulmonary, gonadal and 
central nervous system status can be significantly ameliorated also when stable mixed chimerism 
is obtained.
110–114
 Indeed, no clinical manifestation correlated with SCD occurred after HSCT in 
our cohort. Since cerebral vasculopathy was the cause for transplant in 7 patients, we focused our 
attention on the evaluation of TCD and brain MRI and MRA. Chronic transfusions resulted in 
normalization of pre-transplant TCD in all patients that received this treatment; however cerebral 
artery stenosis were visible on pre-HSCT MRA for all 7 patients. Post-HSCT MRA data were 
available for 5 patients and showed either a stabilization of the stenosis or an amelioration, as 
judged by an experienced radiologist. The evidence of improvement in vascular stenosis 
compares favorably with previous reports and was reported in patients treated with chronic 
transfusion, hydroxycarbamide or HSCT.
107,115–118
 These satisfactory outcomes could be possibly 
due to the screening program for cerebral vasculopathy performed at our center and to the fact 
that all patients were transplanted before any clinically evident stroke.
119
  
The safety profile of Treosulfan conditioning regimen was excellent and incidence of adverse 
events was comparable to previous reports: no transplant-related mortality was observed and 
grade III-IV non hematological toxicity was limited to mucositis which resolved completely 
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without sequelae.
95,96
 The neurological event in our case series cannot be attributed with 
certainty to the Treosulfan conditioning. This toxicity profile is similar to results obtained in 
adult patients transplanted after a non-myeloablative conditioning.
120–123
 Grade I-II acute GvHD 
was observed in 3/11 patients in our cohort (27%) with no grade III-IV acute GvHD or chronic 
GvHD. The GvHD cases were all among patients receiving an alternative donor transplant and 
no GvHD was observed among the 7 patients receiving a MSD HSCT and all the patients 
experiencing GvHD responded rapidly to first line treatment. To the best of our knowledge, 
organ damage related to HSCT has not been previously reported for SCD patients undergoing 
HSCT after a Treosulfan-based conditioning regimen. In our cohort, the decline in pulmonary 
and renal function observed after Busulfan-based conditioning regimen was not present and 
growth, thyroid, gonadal and cardiac function were preserved after HSCT. 
107,110
 
Current knowledge about outcomes of Treosulfan based conditioning regimen in SCD is limited 
to a single-center experience reporting 15 patients who received a MSD or MUD HSCT. 
96
 We 
have nearly doubled the number of reported patients and we have described the use of 
Treosulfan-based conditioning regimen for MMUD or haploidentical donor HSCT, which are 
considered investigational approaches in SCD.
 70,88,107
 To mitigate the risk of rejection and 
GvHD, TCRαβ+ and CD19+ cell depletion was performed on PBSC.64 In the MMUD setting, 
this approach was reported as safe and efficacious for patients with acute myeloid leukemia or 
Hurler syndrome but no SCD patient has been described yet.
124,125
 If further investigations will 
confirm its feasibility and efficacy, haploidentical or MMUD HSCT in SCD may open the 
possibility of cure for many patients without a MSD or MUD donor available.
89–91
 When 
employing alternative donors, a higher risk of GvHD and delayed immune reconstitution should 
be taken into account; however, in our experience, these drawbacks can be managed by 
supportive therapy and are outweighed by the satisfactory outcomes. Although PBSC 
mobilization with G-CSF in HbS heterozygous parents is often perceived as risky, no significant 
adverse events were reported and, in our experience, both the haploidentical donors underwent 
PBSC mobilization and collection safely.
126,127
 
The main limitation of our study is its retrospective nature and the report of a single center 
experience; sample size was also limited and warrants further confirmation. Moreover, in order 
to perform the TCRαβ/CD19 depletion, a facility with experience in stem cell manipulation is 
needed. 
In conclusion, our data show that HSCT after Treosulfan based conditioning regimen for SCD 
patients is effective and associated with low toxicity. End organ damage may be halted or even 
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ameliorated as shown by the regression of cerebral vessel stenosis and white matter changes. 
This strategy is suitable also for alternative donor transplants and, if our data is confirmed in 
larger cohorts, could pave the way for expanding the access to HSCT to SCD patients lacking a 
matched sibling or matched unrelated donor. 
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2.2 Haploidentical Hematopoietic Stem 
cell Transplantation cures 
autoimmune hepatitis and 
cerebrovascular disease in a patient 
with Sickle Cell Disease  
Submitted for publication 
 
Sickle Cell Disease (SCD) may lead to several acute and chronic complications and the end-
organ damage may be aggravated by co-existing conditions.
128
 Among SCD patients, 
autoimmune disorders, such as autoimmune hepatitis (AIH) or systemic lupus erythematosus, are 
not infrequent and are difficult to treat due to the high risk of adverse events associated with 
steroids or other immunosuppressive treatments.
129–131
 Hematopoietic Stem Cell Transplantation 
is the most consolidated curative therapy for patients with SCD, but benefits and risks in both the 
short and long term must be carefully considered, taking into consideration disease variability 
and the recent appearance of new drugs. Despite the progressive broadening of indications for 
HSCT,
106
 the majority of pediatric hematologists still offers it only to patients with a severe 
phenotype: cerebrovascular disease, recurrent vaso-occlusive crises (VOC) or acute chest 
syndrome not responsive to Hydroxycarbamide, or sickle nephropathy.
119,132
 HSCT is also an 
option for the management of severe autoimmune disorders such as multiple sclerosis, systemic 
sclerosis and rheumatoid arthritis, but it has not been previously reported for autoimmune 
hepatitis.
133
 We report a patient with SCD and AIH, both cured after HSCT. 
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Our patient was diagnosed with HbSS SCD at the age of 4 years when she was hospitalized for 
severe hemolytic anemia. At the age of 7 years, Trans-Cranial Doppler (TCD) showed a velocity 
> 200 cm/sec in both the middle cerebral arteries and the basilar artery with a normal brain 
Magnetic Resonance Imaging (MRI) and Magnetic Resonance Angiography (MRA). The patient 
began a regular blood transfusion program for stroke prevention, which was changed to monthly 
red cell exchange transfusions (ECA) at the age of 8 years when adequate venous lines could be 
placed. At the age of 11 years, severe stenosis of the carotid syphon and middle cerebral arteries 
and moderate stenosis of the anterior cerebral arteries seen on MRA (Figure 1A) prompted ECA 
to be scheduled every three weeks to maintain HbS under 30%. At the age of 13 years, 
MRI/MRA showed a minimal reduction of arterial stenosis with a concomitant normalization of 
TCD, which was confirmed two years later. No clinical or subclinical stroke occurred. 
Figure 1 MRA of intracranial arteries pre and post-HSCT. 
A. MRA performed at the age of 11 years showing bilateral severe stenosis of the distal internal carotid arteries 
(arrows), proximal middle cerebral arteries (arrow heads) and their branches.  
B. One year after HSCT, the intracranial arteries appears almost normal. 
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At the age of 13 years the patient was hospitalized for cholestatic jaundice (total bilirubin 277,1 
µmol/L, conjugated bilirubin 171,2 µmol/L) and elevation of liver enzymes (AST 1188 U/L, 
ALT 974 U/L and GGT 188 U/L). Liver infection, liver sequestration and disorders of the biliary 
tree were excluded by appropriate investigations including Magnetic Resonance Cholangio-
Pancreatography. Anti-nuclear and anti-smooth muscle antibodies resulted positive at a titer of 
1:320 and >1:80 respectively, and hypergammaglobulinemia was noticed (IgG 25 g/L). The 
diagnosis of type I AIH was confirmed by liver histology, which showed portal and peri-portal 
fibrosis, portal inflammatory infiltrates (mostly constituted of lymphocytes and plasmacells) and 
focal areas of necrosis (Figure 2). Treatment with prednisolone was initiated with prompt 
normalization of liver enzymes and resolution of cholestasis, and one month later azathioprine 
was added after having excluded TPMT variants. Steroid treatment was tapered and discontinued 
5 months after the diagnosis of AIH but was resumed one month later due to disease relapse. In 
Figure 2 Representative histological features of the liver biopsy. 
Histological examination of the liver biopsy showed a high-grade lymphocytic and plasma cell infiltrate within 
the portal tracts (A), associated with interface hepatitis (B). Some portal tracts were moderately enlarged by 
portal/periportal fibrosis (C). The histological features were consistent with the diagnosis of chronic active 
hepatitis and compatible with an autoimmune etiology. (D) Red blood cells within the liver sinusoids disclosed 
the characteristic sickle cell shape. (H&E and Van Gieson stain; original magnification 10x and 40x). 
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the following four years, the patient experienced two relapses of AIH, demonstrating the 
absolute need of constant immunosuppression with steroids and azathioprine. The anti-nuclear 
and anti-smooth muscle autoantibodies remained persistently positive during follow-up, with a 
fluctuating titer corresponding to disease activity. Due to appearance of recurrent and severe 
VOCs while assuming steroids, exchange transfusions were performed every 18-20 days. 
At the age of 16 years, the patient underwent a HSCT after conditioning with Treosulfan, 
Fludarabine, Thiotepa, Rituximab and Graphalon® anti-thymocyte globulins. The intensive 
transfusion program required to control the cerebrovascular disease as well as the recurrent 
VOCs constituted the main indication for HSCT. Due to the lack of a matched sibling donor or a 
matched unrelated donor, her HbSA haploidentical father was employed as a donor and an ex-
vivo TCRαβ and CD19 depletion on PBSC (Peripheral Blood Stem Cell) was performed.134 The 
regimen-related toxicity included grade 4 thrombocytopenia, grade 3 anemia, grade 3 febrile 
neutropenia and grade 3 mucositis, all resolving completely. No post-transplant immune 
suppression was given and all treatments for AIH were interrupted before the beginning of 
conditioning. On day + 35 post HSCT, the patient presented with fever, abdominal pain and 
anorexia; a gastric and rectal biopsy showed histological signs of Graft-versus-Host disease 
(GvHD) and the patient was diagnosed with grade II acute GvHD. She received treatment with 
cyclosporine and extracorporeal photochemotherapy, which resulted in complete remission of 
symptoms within one week. Cyclosporine was continued for one month and extracorporeal 
photochemotherapy for 4 months. At two years post-HSCT, chimerism analysis showed a full 
donor hematopoiesis, no SCD manifestation occurred, cerebral vasculopathy resolved almost 
completely (Figure 1B) and the patient was without any medical treatment. The patient did not 
experience any relapse of AIH and anti-nuclear and anti-smooth muscle autoantibodies were 
found negative two months after HSCT and thereafter.  
AIH is a liver disease with a wide spectrum of manifestations, ranging from asymptomatic 
hypertransaminasemia to decompensated cirrhosis and acute liver failure. Its treatment usually 
consists of long-term immune suppression with steroids and azathioprine; however, unresponsive 
and severe cases may require intensive treatment including liver transplantation.
135
 Our report 
shows that allogenic HSCT may be a cure for AIH and this finding is especially important for 
patients with AIH and a concomitant hematological disorder. The autoimmune disorders in 
patients with SCD pose diagnostic and treatment dilemmas and lead to a significant worsening in 
the overall health and quality of life. The Treosulfan-based conditioning regime was well 
tolerated without any liver toxicity and resulted in a stable engraftment notwithstanding the 
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employment of a non-conventional haploidentical donor. In particular, the haploidentical HSCT 
for our patient was performed with a TCRαβ and CD19 deplete PBSC graft without post 
transplant immune suppression, demonstrating that the HSCT itself was responsible for the cure 
of AIH. Moreover the benefits of this platform include the almost universal donor availability 
permits to reduce the toxicity associated with the use of calcineurin inhibitors or other immune-
suppressive agents. In conclusion, we suggest that the diagnosis of an autoimmune disorder in a 
patient with SCD might be an indication for HSCT. Further prospective trials are necessary to 
confirm on larger cohorts the observed benefits of HSCT in terms of morbidity, organ damage 
and need for medical treatment. 
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Chapter 3 
 Outcomes of children with 
Hemophagocytic Lymphohistiocytosis 
given allogeneic Hematopoietic Stem 
Cell Transplantation in Italy 
Presented as Oral presentation: 
Marzollo A., Messina C., Zecca M., Fagioli F., Rovelli A., Lanino E., Bertaina A. , Porta F., 
Aricò M., Sieni E., Basso G., Ripaldi M., Favre C., Pillon M., Rabusin M., Merli P., Caniglia M., 
Saglio F., Prete A., Locatelli F., Outcomes of children with Hemophagocytic 
Lymphohistiocytosis given allogeneic Hematopoietic Stem Cell Transplantation in Italy, 
2017 Meeting of the European Society for Immunodeficiency 
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Abstract  
Patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for 
Hemophagocytic Lymphohistiocytosis (HLH) are a population with specific peculiarities, 
warranting special considerations about timing of HSCT, donor choice and conditioning 
regimen. We report here the largest cohort of HLH patients undergoing HSCT. Included in the 
analysis were 109 patients undergoing 126 transplant procedures between 2000 and 2014 in 
centers associated with the Italian Pediatric Hematology Oncology Association (AIEOP). 
Genetic diagnosis was FHL2 (32%), FHL3 (33%) or other defined disorders known to cause 
HLH (20%). Donor for first transplant was an HLA-matched sibling for 25 patients (23%), an 
unrelated donor for 73 patients (67%) and a partially matched family donor for 11 patients 
(10%). Conditioning regimen was busulfan-based for 61 patients (56%), treosulfan-based for 21 
patients (20%) and fludarabine-based for 26 patients (24%). The 5-year probability of overall 
and event-free survival were 71% and 60% respectively. Death was mainly due to transplant-
related mortality (TRM), while 12 out of 14 patients undergoing a subsequent transplant for 
rejection/relapse were salvaged. Use of HLA-partially-matched family donor and use of 
peripheral blood stem cells were associated with adverse outcome in univariate analysis, while 
only the former variable remained significant in multivariate analysis. Active disease at 
transplantation did not significantly affect prognosis. These data suggest that active disease 
should not preclude transplantation, which should be performed preferably using either bone 
marrow or cord blood cells. Since HLA-haploidentical HSCT in patients with HLH is currently 
associated with unsatisfactory outcomes, innovative approaches are warranted.  
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3.1 Introduction 
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening, hyper-inflammatory 
syndrome, characterized by cytopenia, fever, hepatosplenomegaly and multi-organ dysfunction. 
It affects children and adolescents with a higher incidence in the first years of life. HLH can be 
secondary to infection, autoimmune disease or cancer. In one third of cases, primary immune 
deficiency resulting in impaired killing of infected cells by T cells or natural killer (NK) cells is 
present (familiar HLH, fHLH).
136
 The genetic defect underlying fHLH results in impaired 
formation and release of cytotoxic granules, and is caused by genes directly implicated in the 
secretory lysosome-dependent exocytosis pathway (PRF1 in FHL2, UNC13D in FHL3, STX11 in 
FHL4, STXBP2 in FHL5).
137
 HLH can also be part of clinical syndromes with other associated 
manifestations, such as Chédiak-Higashi syndrome, Griscelli syndrome type 2, Hermansky-
Pudlak syndrome type 2, X-linked lymphoproliferative disease type 1 and 2.
138
 Approximately, 
70% of fHLH in Southern Europe are caused by PRF1 and UNC13D mutation.
139
 
Chemo-immunotherapy with dexamethasone, etoposide and cyclosporine-A (CsA) can control 
the inflammatory manifestation in around 60-80% of the cases.
140,141 
However, for patients with 
fHLH or relapsed/refractory HLH, allogeneic hematopoietic stem cell transplantation (HSCT) is 
the only curative treatment.
142
  
HSCT in a patient with HLH was first reported in 1986 and many case series have since been 
described.
143
 Significant-transplant related mortality (TRM) was reported in earlier experiences 
with an overall survival of 45-65%.
144–146 
This observation has prompted the use of conditioning 
regimens less toxic than the traditional Busulfan-based myeloablative regimen. The use of 
Fludarabine or Treosulfan permitted to gradually reduce TRM with better outcomes.
147,148 
The 
major drawbacks related to the use of less toxic regimens including fludarabine/treosulfan are a 
relevant incidence of mixed chimerism and overt rejection. 
102,149
  
In this study, we present the outcomes of a cohort of 109 patients affected by HLH who 
underwent HSCT in centers affiliated with the Italian Pediatric Hematology Oncology 
Association (AIEOP) network between 2000 and 2014.   
3.2 Methods 
In this study, we collected data reported to the AIEOP Stem Cell Transplantation Registry and 
selected patients according to the following criteria: 1) diagnosis of a) fHLH b) a genetic 
disorder predisposing to HLH c) clinical HLH without genetic markers not responding to chemo-
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immuno-treatment or relapsing after treatment 2) HSCT performed in one of the centers 
participating in the AIEOP network 3) transplantation date comprised between January 1
st
, 2000 
and December 31
st
, 2014.
 16
 Whenever needed, centers were contacted for further information 
about patient status before HSCT, details of the procedure and outcomes. We excluded patients 
without adequate data available. Forty-two patients included in this cohort have been previously 
reported.
150
 
Patients or legal guardians signed written informed consent for collection, analysis and 
publication of relevant data. Genetic diagnosis was centrally performed at Meyer Children 
Hospital in Firenze, Italy, as previously described.
136 
Central Nervous System (CNS) involvement was considered present if a patient had any of the 
following findings: elevated cerebrospinal fluid (CSF) white cell count, clinical symptoms 
consistent with CNS involvement (such as seizures or focal or global neurologic deficit), 
Magnetic Resonance Imaging (MRI) abnormalities consistent with CNS involvement. 
Patient status before HSCT was defined according to the following criteria: 1) Complete 
Response: normalization of all diagnostic clinical and laboratory abnormalities associated with 
HLH; 2) Partial Response: sustained normalization of three or more of the diagnostic parameters 
previously validated
 
and no apparent progression of other parameters;
151
 3) Non-Response: 
normalization of less than two diagnostic parameters or clear progression of other aspects of 
HLH disease. 
After HSCT, disease relapse was defined as recurrence of symptoms typical of HLH with re-
establishment of recipient hematopoiesis; rejection was defined as immunologically-mediated 
graft failure.  
3.2.1 Definitions and statistical analysis 
The primary endpoint was event-free survival (EFS), defined as the probability of being alive 
and in continuous CR at last follow-up. In order to determine EFS, death from any cause, relapse 
or graft failure were considered events. Occurrence of stable mixed chimerism without signs and 
symptoms of HLH was not considered an event. Full donor chimerism was defined as presence 
of ≥95% leucocytes of donor origin in peripheral blood or bone marrow. Secondary endpoints 
were overall survival (OS), time to neutrophil and platelet recovery, incidence of relapse (RI), 
TRM, acute and chronic GvHD. Probabilities were calculated from date of transplantation until 
the event or last follow-up.  
Neutrophil engraftment was defined as achieving an absolute neutrophil count ≥0.5x109/L for 
three consecutive days with no evidence of autologous recovery (i.e. <5% leucocytes of donor 
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origin in peripheral blood or marrow). Platelet engraftment was defined as achieving a platelet 
count ≥20x109/L unsupported through platelet transfusions for 7 days. Acute GvHD occurrence 
was evaluated in all patients with myeloid engraftment, while chronic GvHD was evaluated only 
in patients surviving beyond day +100 after HSCT. Acute and chronic GvHD were graded 
according to previously published criteria.
152,153
  
Quantitative variables were reported as median value and range, while categorical variables were 
expressed as absolute value and percentage. Probabilities of EFS and OS were calculated using 
the Kaplan-Meier estimates. Cumulative incidence functions (CIF) were used to estimate RI and 
TRM in a competing risks setting, as death and relapse compete with each other. To estimate 
acute and chronic GvHD incidences, relapse and death were considered as competing events. 
A comparison with two sided p-value of less than 0.05 was considered statistically significant. 
Variables reaching a p-value of less than 0.10 in univariate analysis were included in Cox 
proportional hazard regression models using a backwards stepwise selection. Statistical analysis 
was performed using NCSS [NCSS 10 Statistical Software (2015). NCSS, LLC. Kaysville, UT, 
www.ncss.com/software/ncss] and R 2.5.0 software package (http://www.R-project.org). 
154,155
 
Analysis used January 31st, 2016 as reference date. 
3.3  Results 
3.3.1  Patient population 
One hundred twelve patients with HLH who underwent 129 transplant procedures have been 
reported the AIEOP HSCT registry. Three patients were not evaluable for this study due to lack 
of data; thus, the final analysis includes 109 patients and 126 transplant procedures performed in 
16 AIEOP centers. Sixty-five patients (60%) were male and 44 (40%) were female. Median age 
at diagnosis was 1 year (range 27 days-18 years), while median age at first transplantation was 2 
years (range 4 months -20 years). Mean time interval between diagnosis and first HSCT was 289 
days (range 26-1844 days). Patient and HSCT characteristics are summarized in Table 4. 
Genetic testing was performed for 96 (88%) out of 109 patients. Mutation of PRF1 was found in 
31 patients (32%), of UNC13D in 32 patients (33%), of STXBP2 in 2 patients (2%), of RAB27A 
in 6 patients (6%), of SH2D1A in 5 patients (5%), of BIRC4 in 2 patients (2%) and of LYST in 1 
patient (1%). No known gene abnormality was found in 15 patients (15%).  
CNS involvement at diagnosis was recorded for 79 patients (72% of the overall population) and 
was present in 30 patients (38%): 17 (22%) had elevated CSF white cell count, 20 (25%) had 
clinical symptoms consistent with HLH and 7 (9%) had MRI abnormalities consistent with HLH.  
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Table 4 Patient and transplant characteristics. 
  N. %  
Gender 
  
Male 65 60% 
Female 44 40% 
Genetic diagnosis 
  
FHL2 31 28% 
FHL3 32 29% 
Griscelli Syndrome 6 6% 
XLP1 5 5% 
Other 7 6% 
No known genetic defect 15 14% 
Study not performed 13 12% 
Age at diagnosis, median (range) 1 y (27d – 18y) 
 
Age at transplant, median (range) 2 y (4m – 20 y) 
 
CNS involvement   
Present 30 28% 
Absent 49 45% 
Data not available 30 27% 
Treatment before transplant 
  
HLH-1994 protocol 9 8% 
HLH-2004 protocol 41 38% 
Euro-HIT-HLH protocol 3 3% 
Other 7 6% 
Unknown 49 45% 
Disease status at first transplant 
  
First complete remission 24 22% 
More advanced complete remission 6 5% 
Partial response 17 16% 
No response 54 50% 
Pre-emptive 2 2% 
Unknown 6 5% 
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  N. %  
Conditioning regimen 
  
Busulfan-based conditioning 61 56% 
Busulfan-Cyclophosphamide 10 9% 
Busulfan-Etoposide 18 17% 
Busulfan-Fludarabine 6 6% 
Busulfan-Thiotepa 22 20% 
Other Busulfan-based conditioning 5 4% 
Fludarabine based conditioning 26 24% 
Fludarabine-Melphalan 12 11% 
Fludarabine-Melphalan-Thiotepa 9 8% 
Other Fludarabine- based 5 5% 
Treosulfan-based conditioning 21 20% 
Treosulfan-Fludarabine-Thiotepa 15 14% 
Treosulfan-Fludarabine 5 4% 
Treosulfan-Fludarabine-Cyclophosphamide 1 1% 
Other conditioning regimen 1 1% 
Donor type 
  
Matched sibling donor 25 23% 
Matched unrelated donor 73 67% 
Partially matched family donor 11 10% 
Stem cell source 
  
Bone marrow 70 64% 
Peripheral blood stem cells 18 17% 
Umbilical Blood Graft 21 19% 
Serotherapy 
  
ATG 76 70% 
Alemtuzumab 7 6% 
No Serotherapy 26 24 
T-Cell depletion   
Ex vivo T-cell depletion 8 7% 
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At diagnosis, 9 patients were enrolled in the HLH-94 protocol,
5
 41 patients were enrolled in the 
HLH-04 trial,
17
 3 in the Euro-HIT-HLH trial [EudraCT#2011-002052-14], 4 received 
personalized treatment, 2 patients were transplanted without any other treatment due to diagnosis 
of BIRC4 mutation before developing clinical HLH and for 49 patients data on the frontline 
treatment are not available. Two patients received anti-IFNɣ monoclonal antibody in the context 
of a clinical trial [EudraCT#2012-003632-23, #NCT01818492].
156 
Multiple intrathecal injections 
of methotrexate were employed for preventing/treating neurological involvement. 
3.3.2 Transplant procedure 
Ninety-five patients received one transplant, while 14 received more than one HSCT because of 
rejection in 8 patients or disease relapse in 6 patients (preceded by rejection in 1 case): 2 
transplants were performed in 12 cases, 3 transplants in 1 case and 4 transplants in 1 case. Thirty 
HSCT were performed between 2000 and 2004, 42 between 2005 and 2009, and 54 between 
2010 and 2014.  
Disease status at first HSCT was known for 102 (94%) out of the 109 patients; 71 patients had 
active disease (no response, n= 54; partial response, n= 17), 24 were in first complete remission 
and 5 were in a later complete remission. Two patients received HSCT due to diagnosis of 
BIRC4 mutation before developing clinical HLH. Conditioning regimen was Busulfan-based for 
61 patients, Treosulfan-based for 21 patients, Fludarabine-based for 26 patients and melphalan-
etoposide for 1 patient (see also Table 4 and Table 5 for further details). 
The donor for the first transplant was an HLA-matched sibling donor for 25 patients, an 
unrelated volunteer selected using high-resolution HLA typing for 73 patients and an HLA-
partially-matched family donor for 11 patients. Seventy patients were transplanted with bone 
marrow-derived stem cells, 18 with peripheral blood stem cells (PBSC), while 21 children 
received umbilical cord blood transplantation. The mean dose of mononuclear cells was 6.4 cells 
x 10^8/kg for bone marrow grafts (range=2.5-27.3 x 10^8/kg) and 11.2 cells x 107/kg (range= 2-
29.2 x 10^7/kg) for cord blood grafts. The mean dose of CD34 positive cells for PBSC grafts 
was 15.9 cells x 10^6/kg (range 2-24.8 x 10^6/kg). 
Considering the 109 first transplants, GvHD prophylaxis consisted of Cyclosporine A in 25 
cases, of the combination of Cyclosporine A and short-term methotrexate in 55 cases, of the 
combination of CsA and steroids in 20 cases. Post-transplant high-dose cyclophosphamide was 
used in 1 case and in vitro T-cell depletion was used in 8 allografts. 
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3.3.3 Engraftment and chimerism 
Neutrophil engraftment after first HSCT was obtained in 100/109 (92%) procedures at a median 
time of 18 days (range 9-57 days). Platelet engraftment after first HSCT was obtained in 87/109 
(80%) cases at a median interval of 24 days (range 9-105 days).  
Stable mixed chimerism with good graft function and clinical remission of HLH was recorded in 
6 patients. Donor contribution to hematopoiesis ranged from 5 to 97%, without evidence of the 
underlying disease. Fourteen patients received a second transplant. The reason for second HSCT 
was disease relapse (n=11) or graft failure (n=3). Subsequent transplants (n=17) were performed 
with Busulfan-based conditioning (n=3), Fludarabine-based (n=5), Treosulfan-based (n=5) or 
other conditioning regimen (n=4). The donor was a matched sibling donor for 2 procedures, a 
partially-matched family donor for 6 procedures and an unrelated donor for 9 procedures. Stem 
cell source was bone marrow and PBSC in 8 transplants each and cord blood for the last 
allograft.  
Neutrophil engraftment after second transplant was obtained in 12/14 (86%) procedures at a 
median time of 17 days (range 11-34 days). Platelet engraftment after second transplant was 
obtained in 11/14 (79%) transplants at a median time of 24 days (range 11-55 days).  
Out of the 14 patients that received a second transplant, 12 (86%) are alive and well at last 
follow-up; however, 1 of them required two further transplant procedures to achieve a good graft 
function. One patient died of viral infection after the second transplant and another of respiratory 
failure after the third transplant.  
Acute GvHD was evaluated among the 115 transplants that resulted in donor engraftment. Grade 
II and grade III-IV acute GvHD occurred in 29 (25%) and11 (9%) transplants, respectively. 
Among 95 HSCT after which the patient did not die or was transplanted again before day 100, 
chronic GvHD was observed in 18 cases (19%): it was of limited severity in 9 cases (9%) and 
extensive in other 9 cases (9%). 
3.3.4 Clinical outcome 
The median observation time for surviving patients is 5.2 years (range 0.9-14.9 years), while it 
was 54 days (range, 7 days-3.8 years) for those who died. 
At time of the last follow-up, 78 patients (72%) are alive, with a 5-year OS for the whole study 
population of 71% (95% CI, 62-79, see also Figure 1). 
A total of 26 patients (24%) died to transplant-related causes at a median of 53 days after HSTC; 
TRM was preceded by graft rejection in 4 cases. The cumulative TRM incidence was 25% (95% 
CI, 18-35). The number of fatal events according to the type of conditioning regimen employed 
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is shown in Table 5, while Table 6 summarizes the causes of death of the whole study 
population; veno-occlusive disease, lung aspergillosis and multi-organ failure were the most 
frequent cause of death. Graft failure was observed in 14 patients (5%) at a median of 20 days 
after HSCT (range, 8-51). 
 
Table 5 Comparison of outcome among Busulfan-based, Treosulfan-based and Fludarabine-based conditioning 
regimens. 
 
Busulfan based 
(n=61) 
Treosulfan 
based 
(n=21) 
Fludarabine 
based 
(n=26) 
Chi square 
P 
 n (%) n (%) n (%)  
Active disease at HSCT 38 (62%) 13 (62%) 20 (74%) N.S. 
        
TRM 16  (26%) 3 (14%) 7 (26%) N.S. 
VOD 4 (7%) 0 (0%) 3 (11%) N.S. 
Rejection 7 (11%) 1 (5%) 6 (22%) N.S. 
Relapse 4 (7%) 2 (10%) 4 (15%) N.S. 
        
Alive 43 (70%) 18 (86%) 17 (63%) N.S. 
Alive & disease-free 37 (61%) 15 (71%) 14 (52%) N.S. 
 
The cumulative incidence of graft failure was 13% (8-21). Four of the 14 patients who rejected 
the transplant died due to transplant-related causes (after a second HSCT in 1 case), while 3 
subsequently developed an overt disease recurrence: 2 died due to disease progression, while 1 
was rescued by a second HSCT. The remaining 7 patients who rejected are alive and disease-free 
after a second transplant. A disease relapse was observed in 10 patients (9%) at a median of 163 
days after HSCT (range, 41-585 days) and was preceded by a primary rejection in 3 cases. The 
cumulative incidence of relapse was 9% (96% CI, 5-17). Eight out of the 10 patients who 
relapsed received a second HSCT; 5 of them are alive and disease-free. 
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Table 6 Causes of death. 
  Number of transplant   
  First HSCT Subsequent HSCT Total 
    Disease progression 4 1 5 
    Veno-occlusive disease 7 0 7 
Lung aspergillosis 5 0 5 
Multi-organ failure 4 1 5 
Viral infection (Adenovirus/Cytomegalovirus) 3 0 3 
Chronic GVHD 2 0 2 
Acute GVHD 1 0 1 
Cerebral hemorrhage 0 1 1 
Thrombotic microangiopathy 1 0 1 
Unknown 1 0 1 
    Total 28 3 31 
 
Sixty-six patients are alive and disease-free after the first HSCT at time of last follow-up, the 5-
year probability of EFS being 60% (95% CI, 50-69). The variables found to be statistically 
associated, in univariate analysis, with EFS were donor type and stem cell source. Patients 
transplanted from partially-matched family donors had a significantly worse EFS (9%; 95% CI, 
0-26%) than recipients of a matched family donor transplant (73%; 95% CI, 54-92%) or a 
matched unrelated donor allograft (63%; 95% CI, 52-74%) (P< 0.001, see also Figure 2). 
Patients given PBSC transplantation had a significantly lower EFS probability (39%; 95% CI, 
16-61) as compared to bone marrow recipients (60%; 95% CI, 48-72%) or cord blood recipients 
(76%; 95% CI, 58-94) ( P = 0.0185). Children who received the transplant within 6 months from 
diagnosis had a better EFS as compared to those transplanted later than 6 months from diagnosis 
(69%; 95% CI, 56-81 vs. 50%; 95% CI 37-64), but the difference was not statistically significant 
(P = 0.069). Details on univariate analysis of variables potentially influencing outcome are 
shown in detail in Table 7. 
In multivariate analysis (Table 8), only the use of a partially matched family donor confirmed its 
statistically significant association with a worse EFS probability, with a relative risk of 12.26 
(95% CI, 2.82-53.35) (P = 0.0008).  
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Table 7 Univariate analysis of factors influencing event-free survival (except for *, data were considered for first 
HSCT only). 
 
N. Events EFS (%) (95% CI) P-value 
      
All patients 109 43 60% (50-69) - - 
      
Genetic diagnosis           
    PRF1 mutation 31 10 67% (50-84) N.S.  
    UNC13D mutation 32 14 55%  (38-73)   
    Other diagnosis 18 5 72%  (52-93)   
    No genetic diagnosis 15 7 53%  (28-79)   
    Study not performed 13 7 45%  (17-73)   
      
CNS involvement at diagnosis           
    Present 37 16 57% (41-73) N.S.  
    Absent 72 27 61% (49-72)   
      
Years of transplant           
    2000-2004 27 13 52% (33-71) N.S.  
    2005-2009 36 15 58%  (42-74)   
    2010-2014 46 15 67%  (54-81)   
      
Time from diagnosis to HSCT           
    < 6 months 56 17 69% (56-81) 0.0699  
    ≥ 6 months 53 26 50% (37-64)   
      
Disease status           
    Active disease (NR or PR)  71 31 56% (44-68) N.S.  
    CR or pre-emptive 31 10 67% (50-84)   
    Missing information 7 2 69% (32-100)  
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 N. Events EFS (%) (95% CI) P-value 
Conditioning Regimen           
    Busulfan-based 61 24 60% (47-72) N.S.  
    Fludarabine-based 27 13 51% (32-70)   
    Treosulfan-based 21 6 70% (50-90)   
      
Donor           
    MFD 25 6 73% (54-92) < 0.001  
    MUD 73 27 63% (52-74)   
    PMFD 11 10 9% (0-26)   
      
Stem cell source           
    BM 70 27 60% (48-72) 0.0185  
    PBSC 18 11 39%  (16-61)   
    UCB 21 5 76%  (58-94)   
      
No. of HSCT (*)           
    First HSCT 109 43 60% (50-69) N.S.  
    Second HSCT 14 4 71% (48-95)   
MFD: matched family donor; MUD: matched unrelated donor; PMFD: partially matched family donor. BM: bone 
marrow; PBSC: peripheral blood stem cells; CB: cord blood. 
 
Table 8 Multivariate analysis of factors influencing event-free survival (data were considered for first HSCT only). 
Variable Relative Risk (95% CI) P 
Interval Diagnosis - HSCT (months) 
      > 6 months vs. < 6 months 1.15 (0.59-2.24) 0.68 
    Donor 
      MUD vs. MFD 2.16 (0.85-5.49) 0.11 
   PMFD vs. MFD 12.26 (2.82-53.35) 0.0008 
    Stem cell source 
      Cord blood vs. Bone marrow 0.48 (0.18-1.28) 0.14 
   Peripheral blood vs. Bone marrow 0.63 (0.21-1.87) 0.41 
MFD: matched family donor; MUD: matched unrelated donor; PMFD: partially matched family donor. 
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3.4 Discussion 
To the best of our knowledge, the cohort presented here is the largest ever reported of HLH 
patients receiving HSCT. Included were mainly patients with genetic diagnosis of fHLH. The 
most frequent genetic lesions involved PRF1 and UNC13D, reflecting the epidemiology in 
Southern Europe.
136
 Twenty-eight patients (25%) without a genetic diagnosis but fulfilling the 
internationally accepted HLH criteria were transplanted for refractory or relapsed HLH.  
We show that allogeneic HSCT is a therapeutic option capable of curing a large proportion of 
patients irrespectively of the genetic defect responsible for the disease, especially if a suitable 
HLA-matched donor is available. The optimal timing for performing HSCT in HLH patients is a 
matter of debate, especially in cases with relapsed or refractory disease. In particular, it is unclear 
whether for relapsed or refractory disease aggressive second-line chemo-immuno-therapy aimed 
at reaching CR before transplant is warranted. Some case series suggest that active disease at 
transplantation might be a risk factor, especially when an HLA-haploidentical donor is used; 
144,146
 however, other data indicate that initial response to treatment (CR after two month of 
treatment) could be more informative about the prognosis.
145,150,157
 Moreover, in the published 
experiences, around 30-60% of patients have been transplanted with active disease, indicating 
that CR is difficult to obtain in many patients with HLH.
102,145–147,150,157 
Our data could shed 
further light on this issue: active disease at transplantation was not statistically associated with 
adverse outcomes, but patients had a tendency for a worse outcomes if the interval between 
diagnosis and transplantation was longer than 6 months. We thus speculate that active disease at 
transplantation could be indicative of a more aggressive form of HLH that would not adequately 
respond to further treatment. The objective should probably be the achievement of the best 
possible response, without postponing HSCT more than 6 months. Treating patients for a longer 
time, aiming at obtaining CR before transplantation, could result in deterioration of the general 
status and make outcomes of transplant worse. Maybe new approaches to HLH immunotherapy, 
such as that based on the use of an anti-IFNγ monoclonal antibody (EudraCT#2012-003632-23, 
#NCT01818492), could lead to better rates of CR at time of transplantation in refractory 
patients.
156 
Donor availability plays an important role in deciding when to perform a transplant. Our data 
indicate that, although a matched sibling donor is the donor of choice, an unrelated donor 
selected using high-resolution molecular typing of HLA loci can be used with comparable 
patient’s outcome. Our study confirms also that the use of umbilical cord blood is a feasible 
option. 
150,158
 In particular, 21 patients (19%) who received a cord blood allograft had outcomes 
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comparable with those of patients given BM cells. Probably, young age at HSCT for HLH 
patients with a consequent favorable ratio of number of cells infused per Kg of recipient body 
weight makes this kind of procedure more appropriate than in other clinical settings.  
 
Our data indicate that, so far, the use of HLA-partially matched family donors is associated with 
a dismal outcome. The investigation of new approaches to HLA-haploidentical transplantation, 
such as that based on depletion of TCR αβ T cell/CD19+ cells, is urgently needed in order to 
improve patient’s outcome and to offer a timely transplant also to patients lacking a matched 
donor.
64 
The main causes of death in our cohort were complications related to HSCT, namely veno-
occlusive disease, lung aspergillosis and multi-organ failure; HLH relapse accounted for 5 deaths 
only. Indeed, busulfan-based myeloablative conditioning for HLH patients has been reported to 
be associated with a high rate of infections, veno-occlusive disease and possibly a higher 
incidence of pulmonary complications. 
144–146,159–161
 To overcome these issues, in the mid-2000s, 
Figure 3 Survival, Event-free survival (EFS), Transplant-related mortality (TRM), Rejection and Relapse for the 109 
patients after the first HSCT. 
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the use of the fludarabine-melphalan conditioning regimen was introduced, leading to less TRM 
and better outcomes, at the expense of higher mixed chimerism and relapse rates. 
16,147,149,162,163
  
 
Recent experiences report excellent results with the use of treosulfan-based conditioning 
regimens, which seem to be associated with less extramedullary toxicity.
148,102
 Our cohort is the 
only one in which the three above conditioning regimens have been used in a significant 
proportion of patients and outcomes could be directly compared (see also Table 2). Although no 
statistically significant differences were observed, a trend towards better OS and EFS after 
treosulfan-based conditioning was evident. In our experience, the high TRM (26%) observed 
with busulfan was not significantly different from that with fludarabine-based regimens. 
Moreover, fludarabine-based conditioning exposed patients to a higher risk of relapse and need 
of a second transplant (see also Table 2). On the other hand, treosulfan-based conditioning 
resulted in lower TRM (14%) with acceptable rates of graft failure (5%) or relapse (10%), this 
translating into a remarkably high rate of cured patients.  
Importantly, patients receiving a second transplant did not have worse outcomes than patients 
transplanted only once. This finding suggests that when a patient does not suffer from significant 
Figure 4 Event-free survival (EFS) according to the type of donor. MFD: matched family donor; MUD: matched unrelated 
donor; PMFD: partially matched family donor. 
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end-organ damage either related to the original disease or to a first HSCT, it is reasonable to 
perform a second allograft in case of relapse or rejection. Future strategies for HSCT in HLH 
patients should probably aim more at mitigating TRM than at reducing relapse or rejection, 
events which could be salvaged by a second procedure. 
The multicenter and retrospective design of our study may have some limitations, such as that of 
lacking information on pre-transplant treatment in a relevant proportion of patients, but describes 
well the current practice in HSCT for HLH. Our results on probabilities of 5-year OS and EFS 
survival obtained in a larger cohort of children were slightly better as compared with other 
similar cooperative studies.
145,158,160,164,165 
These data might be explained by the higher 
proportion of patients receiving fludarabine- or treosulfan-based conditioning in our cohort or by 
the fact that we included only patients transplanted after 2000. 
In conclusion, our data suggest that in patients with HLH allogeneic HSCT is able to definitively 
cure two thirds of patients, restoring normal immune response towards pathogens and abrogating 
the hyper-inflammatory state typical of HLH. Haploidentical HSCT in patients with HLH is 
currently associated with unsatisfactory outcomes and new approaches are needed to ameliorate 
the outcomes. The use of PBSC should be discouraged, while active disease does not preclude 
transplantation, which should be ideally performed within 6 month from diagnosis. Finally, the 
use of treosulfan-based conditioning could be an attractive option to reduce TRM. 
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Chapter 4 
Supportive treatment and 
psychological consequences of HSCT 
In this chapter are summarized other studies in which the PhD candidate was involved and that 
are focused on supportive care before and after HSCT, and psychological consequences of 
HSCT in children. 
4.1 Eltrombopag use in a patient with Wiskott-Aldrich syndrome 
 
Published as: Gabelli M., Marzollo A., Notarangelo LD., Basso G., Putti MC. Eltrombopag use 
in a patient with Wiskott-Aldrich syndrome. Pediatr Blood Cancer. June 2017. 
doi:10.1002/pbc.26692. 
 
Wiskott-Aldrich syndrome (WAS) is an inherited X-linked recessive disorder characterized by 
microthrombocytopenia, immunodeficiency and eczema. Affected individuals have an increased 
risk of autoimmune and neoplastic disorders; mortality is high during childhood and adolescence 
due to infections, bleeding or malignancies. Although immunodeficiency is variable in 
presentation and severity, thrombocytopenia is a constant feature, is responsible for fatal 
bleeding in 25% of patients and a very low platelet count is currently considered an indication 
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for definitive treatment.
166–168
 HSCT from a matched sibling or a matched unrelated donor is the 
treatment of choice and should be performed in children under the age of 5 years.
169
 HSCT or 
gene therapy may require several months to be performed and, in the meantime, other treatment 
option include splenectomy and platelet transfusion. 
170
 However, splenectomy increases the risk 
of severe infections, particularly after HSCT and platelet transfusions are short-lived, may lead 
to alloimmunisation and may not be effective in all patients.
167,171
 Eltrombopag, a 
thrombopoietin (TPO) receptor agonist, is a new efficient treatment for immune 
thrombocytopenia in both adults and children and may also be used for inherited form of 
thrombocytopenia. 
172–176
 A male with WAS, profound thrombocytopenia, and bleeding diathesis 
successfully was successfully managed with Eltrombopag before HSCT. Eltrombopag was given 
for 32 weeks obtaining a stable platelet count without any platelet transfusion. The patient did 
not experience any bleeding symptom. This treatment reduced bleeding symptoms and 
completely eliminated the requirement for platelet transfusion. Our case adds to the cumulative 
knowledge regarding the efficacy of Eltrombopag in patients with WAS as an effective measure 
to manage profound thrombocytopenia and recurrent bleeding while awaiting definitive 
treatment.
174
 In particular, we suggest that it may be suitable for children under the age of 2 for 
whom bleeding is the first severe manifestation of WAS and may be fatal.
167,168
 Eltrombopag 
treatment was very well tolerated and its oral formulation is suitable also for smaller children. 
Moreover, also a relatively small platelet rise due to treatment may be sufficient to prevent 
severe bleeding. 
4.2 Risk Factors and Outcomes Related to Pediatric Intensive Care Unit Admission 
after Hematopoietic Stem Cell Transplantation: A Single-Center Experience 
 
Published as: Pillon M., Amigoni A., Contin A., Cattelan M., Carraro E., Campagnano E., 
Tumino M., Calore E., Marzollo A., Mainardi C., Boaro MP., Nizzero M., Pettenazzo A., Basso 
G., Messina C. Risk Factors and Outcomes Related to Pediatric Intensive Care Unit 
Admission after Hematopoietic Stem Cell Transplantation: A Single-Center Experience. 
Biol Blood Marrow Transplant. 2017;23(8):1335-1341. doi:10.1016/j.bbmt.2017.04.016. 
 
To describe incidence, causes, and outcomes related to pediatric intensive care unit (PICU) 
admission for patients undergoing hematopoietic stem cell transplantation (HSCT),we 
investigated the risk factors predisposing to PICU admission and prognostic factors in terms of 
patient survival. From October 1998 to April 2015, 496 children and young adults (0 to 23 years) 
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underwent transplantation in the HSCT unit. Among them, 70 (14.1%) were admitted to PICU. 
The 3-year cumulative incidence of PICU admission was 14.3%. The main causes of PICU 
admission were respiratory failure (36%), multiple organ failure (16%), and septic shock (13%). 
The overall 90-day cumulative probability of survival after PICU admission was 34.3% (95% 
confidence interval, 24.8% to 47.4%). In multivariate analysis, risk factors predisposing to PICU 
admission were allogeneic HSCT (versus autologous HSCT, P = .030) and second or third HSCT 
(P = .018). Characteristics significantly associated with mortality were mismatched HSCT (P = 
.011), relapse of underlying disease before PICU admission (P < .001), acute respiratory distress 
syndrome at admission (P = .012), hepatic failure at admission (P = .021), and need for invasive 
ventilation during PICU course (P < .001). Our data indicate which patients have a high risk for 
PICU admission after HSCT and for dismal outcomes after PICU stay. These findings may 
provide support for the clinical decision-making process on the opportunity of PICU admission 
for severely compromised patients after HSCT. 
4.3 Quality of Life and Psychopathology in Adults Who Underwent Hematopoietic 
Stem Cell Transplantation in Childhood: A Qualitative and Quantitative Analysis 
 
Published as: Sinatora F., Traverso A., Zanato S., Di Florio N., Porreca A., Tremolada M., 
Boscolo V., Marzollo A., Mainardi C., Calore E., Pillon M., Cattelan C., Basso G., Messina C. 
Quality of Life and Psychopathology in Adults Who Underwent Hematopoietic Stem Cell 
Transplantation (HSCT) in Childhood: A Qualitative and Quantitative Analysis. Front 
Psychol. 2017;8(AUG):1316. doi:10.3389/fpsyg.2017.01316. 
 
Patients who undergo pediatric Hematopoietic Stem Cell Transplantation (HSCT) may 
experience long-term psychological sequelae and poor Quality of Life (QoL) in adulthood. This 
study aimed to investigate subjective illness experience, QoL, and psychopathology in young 
adults who have survived pediatric HSCT. The study involved patients treated with HSCT in the 
Hematology-Oncology Department between 1984 and 2007. Psychopathology and QoL were 
investigated using the SCL-90-R and SF-36. Socio-demographic and medical information was 
also collected. Finally, participants were asked to write a brief composition about their 
experiences of illness and care. Qualitative analysis of the texts was performed using T-LAB, an 
instrument for text analysis that allows the user to highlight the occurrences and co-occurrences 
of lemma. Quantitative analyses were performed using non-parametric tests (Spearman 
correlations, Kruskal-Wallis and Mann-Whitney tests). Twenty-one patients (9 males) 
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participated in the study. No significant distress was found on the SCL-90 Global Severity Index, 
but it was found on specific scales. On the SF-36, lower scores were reported on scales referring 
to bodily pain, general health, and physical and social functioning. All the measures were 
significantly (p < 0.05) associated with specific socio-demographic and medical variables 
(gender, type of pathology, type of HSCT, time elapsed between communication of the need to 
transplant and effective transplantation, and days of hospitalization). With regard to the narrative 
analyses, males focused on expressions related to the body and medical therapies, while females 
focused on people they met during treatment, family members, and donors. Low general health 
and treatment with autologous HSCT were associated with memories about chemotherapy, 
radiotherapy, and the body parts involved, while high general health was associated with 
expressions focused on gratitude (V-Test ± 1.96). In conclusion, pediatric HSCT survivors are 
more likely to experience psychological distress and low QoL in adulthood compared with the 
general population. These aspects, along with subjective illness experience of the survivor, show 
differences according to specific medical and socio-demographic variables. Studies are needed in 
order to improve the care and long-term follow-up of these families. 
4.4 Psychopathological Aspects in Childhood Hematopoietic Stem Cell 
Transplantation: The Perception of Parents and Adolescents. 
 
Published as: Zanato S., Traverso A., Tremolada M., Sinatora F., Porreca A., Pozziani G., Di 
Florio N., Capello F., Marzollo A., Tumino M., Cattelan C., Basso G., Messina C. 
Psychopathological Aspects in Childhood Hematopoietic Stem Cell Transplantation 
(HSCT): The Perception of Parents and Adolescents. Front Psychol. 2017;8(April):272. 
doi:10.3389/fpsyg.2017.00272. 
 
Data about psychosocial sequelae of HSCT in children are limited and the association with a 
specific donor type or other medical factors is largely unknown. The aim of the present study 
was to compare the psychological aspects of pediatric HSCT survivors with healthy peers. A 
secondary aim was to detect whether parents and children differed in the perception of mental 
health status. The influence of medical factors on psychological status was also examined. Thirty 
seven HSCT survivors (23 males) with a mean age of 14.4 years (SD = 3.03; range 8.16–18.33) 
were recruited. Twenty-six patients underwent an allogenic HSCT (matched unrelated donor, n = 
20; matched sibling donor, n = 6) and 11 patients received an autologous HSCT. The children 
 52 
 
psychological aspects were assessed using the Youth Self Report (YSR) and compared to a 
group of matched healthy peers. At the same time, parents were requested to complete the Child 
Behavior Checklist 6–18. Medical and socio-demographic data were also collected. HSCT 
survivors reported significantly higher levels of somatic complains (t27 = 3.14; p = 0.004; mean 
= 3.1) when compared to healthy peers (mean = 1.5). The parent CBCL scores on “child total 
competence” exceeded the normative clinical cutoff in 48.6% cases. Inter-rater agreement 
between parent and patient reports was present only in three scales: total competence score (K = 
0.06, p = 0.002), somatic complaints (K =0.21, p=0.003) and attention problems (k =0.13; 
p=0.02). According to Ancova models, internalizing problems were more frequent in HSCT 
from family donors (F2 = 3.13; p = 0.06) or in the presence of acute complications (F1 = 11.95; 
p = 0.003). In contrast to the perception of parents, pediatric HSCT survivors reported good 
psychological health. However, they complained about more somatic problems as compared with 
healthy peers. Medical aspects such as donor source and the presence of acute complications 
should be taken into consideration for the psychological approach in order to improve pediatric 
HSCT survivor care. 
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